Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 8/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 4/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758543 | 0.92 | AR (0.41) | EPHX2ARIDO1 | |
| SCHEMBL695762 | 0.90 | PDK2 (0.39) | MGLLARPDK2LTA4HTSHR | |
| SCHEMBL694728 | 0.85 | LTA4H (0.50) | EPHX2MGLLARPDK2LTA4H | |
| SCHEMBL694270 | 0.80 | AR (0.51) | ARPDK2PPARG | |
| SCHEMBL695243 | 0.78 | EPHX2 (0.54) | EPHX2PPARG | |
| SCHEMBL1129534 | 0.78 | MEN1 (0.44) | MGLLARPDK2LTA4HTSHR | |
| SCHEMBL506626 | 0.78 | LTA4H (0.43) | LTA4HTSHRNR1H2 | |
| SCHEMBL696462 | 0.77 | LTA4H (0.49) | PDK2LTA4HTSHRNR1H2NR1H3 | |
| SCHEMBL27531729 | 0.77 | LTA4H (0.57) | EPHX2ARLTA4HNR1H2NR1H3 | |
| SCHEMBL17274291 | 0.76 | NAAA (0.50) | LTA4HTSHRNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421835-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | Glaxo Group Limited (GB) | 2012-02-29 | — | — | EP | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | EPHX2 367/4885MGLL 1257/4885AR 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.